Orudis (Ketoprofen)

Ketoprofen blocks the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which are required for the production of prostaglandins. By lowering prostaglandin levels, it diminishes the inflammatory response, pain signalling and fever at the site of tissue injury.

The appropriate dose of Orudis is determined by the prescribing clinician based on the patient’s condition, age, weight and overall health. The prescriber will set the strength, frequency and duration of therapy in accordance with clinical guidelines.

Ketoprofen is generally avoided in the third trimester of pregnancy because of potential risks to the fetus. Use during early pregnancy should be considered only if the benefit outweighs the risk. Breast‑feeding mothers should consult a healthcare professional, as ketoprofen can be excreted in milk.

To request Orudis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ketoprofen offers analgesic and anti‑inflammatory potency comparable to ibuprofen and diclofenac, with a relatively rapid onset of action. Its pharmacokinetic profile may provide longer pain control after a single dose, but the safety considerations, especially gastrointestinal and renal risks, are similar across the NSAID class.

Orudis tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and heat. Keep the container tightly closed and out of reach of children.

Orudis is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with meals can reduce the chance of stomach irritation.

Serious adverse events linked to ketoprofen include gastrointestinal bleeding or ulceration, severe skin reactions such as Stevens‑Johnson syndrome, kidney injury, liver toxicity and life‑threatening allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they notice any of these symptoms.

Orudis should be avoided by individuals with known hypersensitivity to ketoprofen or other NSAIDs, patients with active gastrointestinal ulcers, severe heart failure, advanced renal or hepatic impairment, and women in the third trimester of pregnancy. A healthcare professional should evaluate suitability before initiating therapy.